Product Images Lurasidone Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Lurasidone Hydrochloride NDC 46708-498 by Alembic Pharmaceuticals Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

lurasidone-120 - lurasidone 120mg

lurasidone-120 - lurasidone 120mg

This is a medication label for a drug called "Urasidone Hydrochloride". The usual dosage is one tablet of 120 mg daily. The manufacturer is not mentioned but there is a product code number.*

lurasidone-20mg.jpg - lurasidone 20mg

lurasidone-20mg.jpg - lurasidone 20mg

lurasidone-40mg.jpg - lurasidone 40mg

lurasidone-40mg.jpg - lurasidone 40mg

This appears to be a prescription label for a medication called Lurasidone Hydrochloride Tablets. The label includes dosage information and contact information for the pharmacy that dispensed the medication. It also mentions the importance of dispensing the accompanying Medication Guide to patients, although no details about the medication's indications or effects are provided.*

lurasidone-60mg.jpg - lurasidone 60mg

lurasidone-60mg.jpg - lurasidone 60mg

lurasidone-80mg.jpg - lurasidone 80mg

lurasidone-80mg.jpg - lurasidone 80mg

lurasidone-figure-1.jpg - lurasidone figure 1

lurasidone-figure-1.jpg - lurasidone figure 1

Impact of other drugs on Lurasidone Pharmacokinetics (PK). The table shows the interacting drugs with Lurasidone, their PK fold change, and 90% CI. The strong CYP3A4 inhibitor, Ketoconazole at a dosage of 400 mg/day, has a significant impact on the Cmax and AUC of Lurasidone. Moderate CYP3A4 Inhibitor, Diltiazem at a dosage of 240 mg/day, shows an impact on Cmax. Besides, Strong CYP3A4 Inducer Rifampin at a dosage of 600 mg/day shows a change in Cmax and AUC. Lithium at a dosage of 600mg BID also shows changes in Cmax and AUC. However, no values are given in the table.*

lurasidone-figure-2.jpg - lurasidone figure 2

lurasidone-figure-2.jpg - lurasidone figure 2

This appears to be a table showing PK (pharmacokinetic) changes in response to interacting drugs for various substances, including P-gp substrates such as Digoxin, CYPIA4 substrates like Midazolam, an oral contraceptive containing Ethinyl Estradiol and Norelgestromin, and Lithium. The table includes measurements for Crmax, Auc, and fold changes relative to the Interactive Drug Alone, as well as a 90% confidence interval.*

lurasidone-figure-3.jpg - lurasidone figure 3

lurasidone-figure-3.jpg - lurasidone figure 3

lurasidone-str.jpg - lurasidone str

lurasidone-str.jpg - lurasidone str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.